Vaccine Market Share by Company
Track the global vaccines sector. GSK, Merck, Pfizer, and Sanofi still collect most branded revenue through Shingrix, Gardasil, Prevnar, and Beyfortus, while Moderna and BioNTech fight the seasonal COVID, RSV, and flu market on mRNA. The investment story is franchise mix (respiratory versus endemic), ACIP and Gavi as demand switches, and a pipeline that is now oncology option-value after the CMV Phase 3 miss and a norovirus Phase 3 interim analysis that did not meet early-success criteria.

The Vaccines sector on Sterling tracks 20 companies.
Vaccines at a Glance
Eight issuer-reported 2025 figures. Four diversified P&Ls still dwarf the mRNA names. Consultant TAM stays out of this strip.
Top Vaccine Franchises, 2025
Named product and franchise sales in USD billions. GBP and EUR converted at IRS 2025 yearly average rates. Color is platform, not company.
Vaccine-Attributable Revenue by Company, 2025
Six public P&Ls, not a summed TAM. GSK, Merck, and Sanofi are issuer vaccines lines. Pfizer is Prevnar plus Comirnaty plus Abrysvo.
2025 Sales by Platform
Classified 2025 sales for GSK, Pfizer, Merck, Sanofi, and Moderna. Other/mixed is pediatric, flu, and residual books that are not a single platform.
Vaccines Public-Equity Universe by Archetype
Eighteen public roster members plus Serum Institute and Bharat Biotech (private), grouped by how they make money in vaccines.
Incumbents
The four diversified vaccines P&Ls. Most branded dollars still sit here.
mRNA platforms
COVID residual plus RSV and flu. Pipeline option-value is now oncology after the CMV Phase 3 miss and a norovirus Phase 3 interim analysis that did not meet early-success criteria.
Flu and protein specialists
Seqirus is the number-two flu manufacturer. Novavax is Nuvaxovid plus Matrix-M: total revenue was $1,123M in 2025 and its 2026 Adjusted Total Revenue framework is $235M to $275M.
Regional, travel, biodefense
Japan/dengue (Takeda), mpox and chikungunya (Bavarian, Valneva), anthrax stockpile (Emergent). Different buyer, different cycle.
Infant RSV adjacency
AstraZeneca co-commercializes Beyfortus with Sanofi. Dual-homed on GLP-1.
China commercial
Zhifei is the cautionary tale for tender-market concentration after the Gardasil destock.
Supply chain
Sterile fill-finish (Thermo Fisher), elastomer components (West), mRNA/LNP CDMO (Lonza). Shared calendar with GLP-1 pens.
Volume manufacturers (private)
Dose volume, not branded P&L. Serum Institute is the Gavi/UNICEF backbone. Bharat is the second India name.
End-to-End Vaccine Stack
Seven layers from antigen to use case. Bar fill is a display weight, not volume share. Fill-finish overlaps the GLP-1 calendar.
Antigen / drug substance
Lipids and adjuvants
Fill-finish
Components
Brand
Buyer
Use case
Sector Milestones, 2020 to 2026
From COVID EUAs to the 2026 seasonal market: ACIP RSV votes, infant mAbs, the CMV Phase 3 miss, the norovirus interim analysis, platform M&A, and mFLUSIVA.
Moderna's Phase 3 CMV vaccine (mRNA-1647) misses its primary efficacy endpoint; congenital CMV program discontinued (22 Oct 2025)
Still no vaccine to prevent congenital CMV. mRNA-1647 continues only in a Phase 2 trial of bone marrow transplant patients.
BioNTech's CureVac exchange offer completes with about 86.75% of shares tendered (18 Dec 2025), ahead of a compulsory acquisition of the rest in early January 2026; Sanofi agrees to buy Dynavax for $15.50 a share, about $2.2B in equity value (agreement 23 Dec 2025, announced 24 Dec 2025)
BioNTech adds to its mRNA design, delivery and manufacturing capabilities; Sanofi adds the marketed adult hepatitis B vaccine Heplisav-B and a Phase 1/2 shingles candidate. Sanofi completed the Dynavax acquisition on 10 Feb 2026.
Novavax grants Pfizer a non-exclusive worldwide Matrix-M adjuvant license for one infectious disease, with a second at Pfizer's option: $30M upfront, up to $500M in milestones across both fields (agreement dated 15 Jan 2026)
Adjuvant becomes a separate cash story from Nuvaxovid COVID volumes, with tiered high mid-single-digit royalties on top.
Bavarian Nordic and Serum Institute of India sign a contract manufacturing agreement for a full tech transfer of the chikungunya vaccine (CHIKV VLP, Vimkunya), announced 11 Mar 2026
Supply to low- and middle-income countries is to be scaled through Serum Institute, replacing the earlier agreement with Biological E.
European Commission announces a joint procurement framework contract with Moderna for up to 24 million mRESVIA doses, signed at the request of 6 countries, with no minimum purchase and a term of up to four years
Public-sector volume for adult RSV in Europe is a ceiling, not a commitment.
FDA approves mFLUSIVA (mRNA-1010) for adults 50+
First US mRNA seasonal flu shot. Traditional approval 50-64; accelerated approval 65+, with a required confirmatory study against high-dose flu vaccine. Demand depends on an ACIP recommendation and 2026-27 contracting.
Phase 3 INTerpath-001 of intismeran autogene (mRNA-4157) plus Keytruda in resected stage IIB-IV melanoma meets its primary endpoint of RFS and key secondary endpoint of DMFS at an interim analysis
Per the companies, the first positive Phase 3 for an individualized neoantigen therapy and for an mRNA cancer therapy. Detailed results on 22 Oct 2026 (ESMO late-breaker LBA1): 42% lower risk of recurrence or death (HR 0.58, 95% CI 0.45 to 0.75) and 38% lower risk of distant metastasis or death (HR 0.62, 95% CI 0.45 to 0.85) versus Keytruda alone; overall survival not yet mature. Phase 2b five-year data (20 Jan 2026) showed a 49% cut in recurrence or death versus Keytruda alone.
FDA approves 2026-2027 Formula COVID-19 vaccines: Comirnaty, Spikevax and mNEXSPIKE (FDA advised a monovalent JN.1-lineage XFG formula)
Comirnaty is approved for adults 65+ and ages 5 to 64 with a high-risk condition. On 28 Aug 2026 Novavax announced its partners' XFG-adapted Nuvaxovid was approved in the US, EU and Japan.
Companies in the Vaccines sector (20)
Related industries
Frequently asked questions
What is the Vaccines sector?
Track the global vaccines sector. GSK, Merck, Pfizer, and Sanofi still collect most branded revenue through Shingrix, Gardasil, Prevnar, and Beyfortus, while Moderna and BioNTech fight the seasonal COVID, RSV, and flu market on mRNA. The investment story is franchise mix (respiratory versus endemic), ACIP and Gavi as demand switches, and a pipeline that is now oncology option-value after the CMV Phase 3 miss and a norovirus Phase 3 interim analysis that did not meet early-success criteria.
Which companies lead the Vaccines sector?
Sterling tracks 20 companies in Vaccines, led by GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
How can I invest in the Vaccines sector?
Publicly traded names in Vaccines include GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY) and Moderna (MRNA). Compare them side by side on Sterling. Data last updated November 1, 2026.